Corcept Therapeutics' second quarter results crushed estimates, driven by a strong Lifyorli launch and raised guidance.

Corcept Therapeutics reported second quarter 2026 revenue of $256.1 million and diluted EPS of $0.36, significantly exceeding analyst expectations. The results were driven by strong initial sales from its newly launched oncology drug, Lifyorli, and continued growth in its Cushing's syndrome business.

Key Highlights

• Revenue grew 32% year-over-year to $256.1 million, beating consensus estimates by 17%.
• The company raised its full-year 2026 revenue guidance to a range of $1.1 to $1.2 billion.
• Newly launched Lifyorli generated $47.6 million in revenue in its first full quarter, well ahead of expectations.
• The New Drug Application (NDA) for relacorilant in Cushing's syndrome was resubmitted, with an expected FDA decision date of December 17, 2026.